Drug intelligence / Profile preview

ROCEN

Development stage: Preclinical
Lead developer: Pharmin USA
Modality: Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

ROCEN is a topical nanoliposomal formulation of avocado/soy unsaponifiables (ASU) developed by Pharmin USA. It is designed to modulate inflammatory and wound-healing pathways by targeting cyclooxygenase (COX) and transforming growth factor beta 1 (TGF-β1). The drug is currently in preclinical development for the treatment of atopic dermatitis, psoriasis, burn wound healing, and inflammatory pain. By utilizing a nanoliposomal delivery system, ROCEN aims to enhance the penetration and efficacy of ASU components in the skin compared to traditional topical applications.

Brand names: ROCEN
Other names: ROCEN 2% Nano-Lipo ASU Topical GelNano-Lipo ASUNanoliposomal Arthrocen topical gel

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)COX

Beyond the preview

Go deeper on ROCEN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ROCEN.

Explore the full profile